Jakarta – In a significant semantic shift that aims to provide a more comprehensive understanding of a prevalent endocrine disorder, the condition previously widely recognized as Polycystic Ovary Syndrome (PCOS) is now being referred to as Polyendokrin Metabolic Ovarian Syndrome (PMOS). This nomenclature change, while maintaining the core diagnostic and treatment approaches, seeks to more accurately reflect the systemic nature of the condition, moving beyond a singular focus on the ovaries.
Dr. M Luky Satria Syahbana Marwali, SpOG, SubspKFER, a specialist in Obstetrics and Gynecology with a subspecialty in Reproductive Endocrinology and Infertility (KFER) at Brawijaya Hospital Antasari, explained the rationale behind this evolution in terminology. For decades, the term PCOS has been deeply ingrained in medical discourse and public awareness. However, Dr. Marwali pointed out that this established name inadvertently creates a misconception, suggesting that the syndrome is confined solely to the ovaries.
"Actually, it’s not just limited to the ovaries, so it’s polyendokrin," Dr. Marwali stated in an interview with detikcom on Monday, May 25, 2026. This statement underscores the central argument for the new designation: the condition’s impact extends far beyond the reproductive organs.
Understanding the Nuances: PMOS vs. PCOS
The expanded acronym, PMOS, breaks down to reveal its more encompassing scope. "Polyendokrin" signifies a disruption across multiple endocrine glands, encompassing hormonal imbalances originating not only in the ovaries but also potentially in the brain (hypothalamus and pituitary gland), kidneys, and adrenal glands. This highlights the intricate network of hormonal regulation that can be affected.
"Polyendokrin" in the context of PMOS encompasses hormonal disturbances, ranging from hormonal imbalances in the brain, kidneys, to the ovaries. Subsequently, "metabolic" refers to metabolic disorders, specifically insulin resistance. The term "ovarian" continues to address the issues within the ovaries.
"So PMOS, Polyendokrin Metabolic Ovarian Syndrome, better illustrates that the disease is indeed a broader condition than PCOS," Dr. Marwali elaborated. This distinction is crucial for healthcare professionals and patients alike, as it prompts a more holistic diagnostic and management strategy. The traditional understanding of PCOS often led to a primary focus on ovarian cysts and menstrual irregularities, potentially overlooking or downplaying other significant systemic manifestations.
"Because if people think of PCOS, they think only of the ovaries, even though there are many other effects from one disease," he added, emphasizing the widespread consequences of the syndrome. These "other effects" can include a range of symptoms and health complications, such as hirsutism (excessive hair growth), acne, weight gain, infertility, type 2 diabetes, cardiovascular disease, and even an increased risk of endometrial cancer.
A Shift in Perspective, Not Treatment
Despite the significant change in nomenclature, Dr. Marwali was quick to reassure that the fundamental approach to diagnosis and treatment remains unchanged. The clinical criteria and diagnostic tools used to identify the syndrome are still applicable, and the therapeutic interventions remain consistent.
"The treatment is still the same, the diagnosis is still the same, everything is the same. It’s just that PMOS describes the disease as a whole," Dr. Marwali concluded. This means that the established management strategies, which often involve lifestyle modifications (diet and exercise), pharmacological interventions to regulate hormones and improve insulin sensitivity, and in some cases, fertility treatments, will continue to be employed.
The shift to PMOS is therefore more of an epistemological and communicative evolution. It aims to foster a deeper understanding of the syndrome’s complexity and its multifaceted impact on a woman’s health, encouraging earlier and more comprehensive intervention.
The Broader Context: Evolution of Medical Understanding
The rebranding of PCOS to PMOS is not an isolated event but rather a reflection of the ongoing evolution of medical science and our deepening understanding of complex diseases. Historically, many medical conditions were named based on their most visible or readily identifiable symptoms, often localized to a specific organ. As research progresses and diagnostic capabilities improve, the interconnectedness of various bodily systems becomes more apparent, necessitating a more holistic nomenclature.
The journey to understanding PCOS began in the 1930s with the description of the condition by American gynecologists Irving Stein and Michael Leventhal. Their initial observations focused on the presence of enlarged ovaries with multiple small cysts, along with irregular menstruation and obesity. Over the subsequent decades, research progressively revealed the hormonal and metabolic underpinnings of the syndrome, highlighting the roles of hyperandrogenism (excess male hormones) and insulin resistance.
The widespread adoption of the term PMOS is likely to be a gradual process, requiring significant educational efforts from medical professionals, public health organizations, and the media. The goal is to ensure that both clinicians and patients are aware of the updated terminology and its implications for understanding and managing the condition.
Supporting Data and Prevalence
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. While precise global prevalence figures can vary due to differing diagnostic criteria and study methodologies, estimates suggest that it affects between 8% and 20% of women worldwide. In Indonesia, similar prevalence rates are observed, making it a significant public health concern.
The metabolic component, particularly insulin resistance, is a critical factor in the pathogenesis and progression of PCOS/PMOS. Studies indicate that a substantial proportion of women with PCOS, often ranging from 50% to 70%, exhibit some degree of insulin resistance, even if they are not overweight or obese. This metabolic dysfunction contributes significantly to hyperandrogenism, ovulatory dysfunction, and an increased risk of developing type 2 diabetes and cardiovascular disease later in life.
The polyendokrin aspect further complicates the picture. Imbalances in hormones like luteinizing hormone (LH), follicle-stimulating hormone (FSH), and androgens are characteristic. Additionally, disruptions in the hypothalamic-pituitary-ovarian (HPO) axis can lead to irregular ovulation and fertility issues. Emerging research also points to the involvement of other endocrine pathways, including the adrenal glands and even the gut microbiome, in the overall endocrine dysregulation seen in PMOS.
Implications for Diagnosis and Management
The transition to PMOS is expected to have several positive implications for the diagnosis and management of affected individuals:
- Holistic Assessment: Healthcare providers will be encouraged to conduct a more comprehensive evaluation, looking beyond just ovarian morphology and menstrual cycles. This includes assessing metabolic health markers like blood glucose and insulin levels, as well as screening for other endocrine abnormalities.
- Early Intervention for Metabolic Complications: By recognizing the inherent metabolic component, there may be a greater emphasis on early identification and management of insulin resistance, thereby mitigating the long-term risks of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
- Improved Patient Education: The clearer nomenclature can empower patients with a better understanding of their condition, fostering greater engagement in treatment plans and lifestyle modifications. When patients understand that PMOS is a systemic issue, they may be more motivated to adopt healthier habits that address multiple aspects of the syndrome.
- Research Focus: The updated term could also guide future research efforts, encouraging studies that explore the interplay between different endocrine systems and metabolic pathways in PMOS, potentially leading to more targeted and effective therapies.
Potential Reactions and Future Directions
While the medical community’s initial reaction is likely to be one of acknowledgment and adaptation, the broader adoption of PMOS will require concerted efforts. Patient advocacy groups are expected to play a crucial role in disseminating information and ensuring that the public understands the significance of this terminology shift.
Medical educational institutions will need to update their curricula to reflect the new terminology and the expanded understanding of the syndrome. Continuous medical education programs for healthcare professionals will be vital to ensure widespread awareness and consistent application of the term.
Looking ahead, the focus will remain on developing personalized treatment plans that address the unique constellation of symptoms and risk factors for each individual with PMOS. Advances in genetic research, endocrinology, and metabolic science will likely continue to refine our understanding and treatment strategies for this complex and prevalent condition. The ultimate goal is to improve the quality of life for millions of women affected by PMOS and to reduce the long-term health sequelae associated with this multifaceted syndrome.
